Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation

lesturner Foundation Blog

Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …

Introducing the First-Ever ALS Platform Trial

lesturner Home Page, Research & The Les Turner ALS Center

The Sean M. Healey & AMG Center at Massachusetts General Hospital is launching the first-ever ALS platform trial aimed at advancing the development of ALS treatments. Our Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine …